Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the Formosan Medical Association = Taiwan yi zhi"
DOI: 10.1016/j.jfma.2019.06.014
Abstract: BACKGROUND Glecaprevir/pibrentasvir (GLE/PIB) is a pangenotypic direct-acting antiviral agent for the treatment of chronic hepatitis C virus (HCV) infection. Real-world data of GLE/PIB in Asian patients other than Japanese are limited. We thus investigated the… read more here.
Keywords: gle pib; safety; chronic hepatitis;
Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in VA Patients with Hepatitis C Virus Infection.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of epidemiology"
DOI: 10.1093/aje/kwac104
Abstract: Our recent exploratory study indicated several direct-acting antivirals (DAAs), highly effective medications for hepatitis C virus (HCV) infection, were also associated with improvement in posttraumatic stress disorder (PTSD) among a national cohort of United States… read more here.
Keywords: sof; acting antivirals; hepatitis virus; gle pib ... See more keywords
IDDF2020-ABS-0013 Effectiveness and safety of glecaprevir and pibrentasvir for hemodialysis patients with hepatitis c virus infection at a single center
Sign Up to like & getrecommendations! Published in 2020 at "Gut"
DOI: 10.1136/gutjnl-2020-iddf.133
Abstract: Background Glecaprevir/pibrebtasvir(GLE/PIB) is anpan-genotypic regimen for the treatment of hepatitis C virus(HCV) infection. GLE and PIB are direct-acting antiviral(DAA)agents that can be used for patients with chronic renal failure who are on hemodialysis(HD) and those… read more here.
Keywords: infection; safety; hemodialysis patients; hepatitis virus ... See more keywords
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s394467
Abstract: Purpose The study aims at investigating the impact of polymedication and aging in the prevalence of multiple drug-drug interactions (DDIs) on HCV patients treated with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). Patients and Methods This is… read more here.
Keywords: sof vel; drug; gle pib;